%0 Journal Article
%T Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
%A Alberto Bosi
%A Brunangelo Falini
%A Chiara Longagnani
%A Daniele Bernardi
%A Elvira Scelzi
%A Enzo Veltri
%A Federico Simonetti
%A Gianfranco Giglio
%A Giovanni Rosti
%A Laura Dorotea
%A Mario Petrini
%A Piero Galieni
%A Roberto Castelli
%A Tommaso Raggi
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2017
%R 10.1177/1758834016670554
%X Many patients with solid tumours or nonmyeloid haematopoietic tumours develop symptomatic anaemia, which has a major impact on quality of life (QoL). The efficacy of erythropoiesis-stimulating agents (ESAs) in improving QoL and reducing blood transfusions has been widely demonstrated. Binocrit£¿ (biosimilar epoetin alfa) is an ESA indicated in the European Union for treating chemotherapy-induced anaemia. The aim of this study was to investigate the effect of Binocrit£¿ on haemoglobin (Hb) levels in anaemic cancer patients in Italian clinical practice
%K biosimilar
%K chemotherapy-induced anaemia
%K epoetin alfa
%K erythropoiesis-stimulating agents
%K erythropoietin
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298451/